Hepatitis/MASH

Top news of the day from across the health care landscape.

Gilead Sciences maker of hepatitis C virus blockbusters Sovaldi, Harvoni, and, most recently, Epclusa has come under increasing scrutiny for declining revenues, both in the near-term and beyond.

Top news of the day from across the health care landscape.

FDA advises nucleic acid tests to screen for hepatitis B virus.

Top news of the day from across the healthcare landscape.

Organ rejection is caused by donor dendritic cells being rapidly replaced by the recipient’s cells.

Hepatitis C testing is often skipped during baby boomer physician office visits.

The impact of antiviral hepatitis C drugs in day-to-day life will be examined.

Patients taking mediations for both HIV and HCV must be closely monitored for drug-drug interactions.

Study will be the first to evaluate the role of metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients.

Direct acting antiviral drugs may increase adverse events after liver transplantation.

Altered flora from antibiotics could affect future drug response and susceptibility to side effects.

Work advances on drug for hepatitis B the rare disease alpha-1 antitrypsin deficiency.

Liver stiffness drops through sustained virological response at 24 weeks with hepatitis C antiviral drug regimen.

New system allows direct absorption of a drug and prevents first past metabolism.

Sophisticated computer model illustrates that stopping hepatitis C within a single US state is a daunting task.

New direct-acting antivirals show great efficacy and limited side effects treating hepatitis C.

Top news of the day from across the health care landscape.

This fixed-dose combination of elbasvir and grazoprevir is indicated to treat chronic HCV genotypes 1 or 4 with or without ribavirin in adults.

Hepatitis B can lead to liver cancer and cirrhosis.

Access to care improves among post liver transplant patients.

Manufacturer coupons found to show significant benefits reducing Sovaldi cost share.

Zepatier is a fixed-dose combination therapy of elbasvir and grazoprevir for chronic hepatitis C.

Drugs that target the signal-peptide peptidase enzyme may halt HCV development.

Baby boomer generation are five times more likely to be diagnosed with hepatitis C virus.